Long-Term Open-Label Safety Study With SkyePharma FlutiForm HFA pMDI [SkyePharma Flutiform(TM) formoterol/fluticasone propionate hydrofluoroalkane pressurised metered dose inhaler] (100/10 microg and 250/10 microg) in adult and adolescent patients with asthma

Trial Profile

Long-Term Open-Label Safety Study With SkyePharma FlutiForm HFA pMDI [SkyePharma Flutiform(TM) formoterol/fluticasone propionate hydrofluoroalkane pressurised metered dose inhaler] (100/10 microg and 250/10 microg) in adult and adolescent patients with asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 19 May 2008 Results will be presented at the American Thoracic Society in Canada.
    • 27 Feb 2008 Status changed from in progress to completed, according to ClinialTrials.gov
    • 29 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top